论文信息 - Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. - 字舞流文

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

A. D’Incecco | M. Rebelatto | M. Maio | D. Giannarelli | R. Danielli | A. Covre | M. Altomonte | L. Calabrò | A. Morra | G. Amato | A. D. Di Giacomo | A. Lewis